Rami Manochakian, Vice President of the North American Neuroendocrine Tumor Society, shared a post on X:
“Hot Off the Press. Big News Press Release by AstraZeneca.
FLAURA2 trial of Osimertinib + Chemotherapy vs Osimertinib in 1st line Therapy for patients with EGFR+ advanced Lung Cancer (NSCLC) shows: Statistically Significant and Clinically Meaningful Improvement in Overall Survival.”
More posts featuring Rami Manochakian.